Qiqi Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Qiqi Yang has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
- David M. Langenau
Massachusetts General Hospital - Charlestown Navy Yard (CNY) Campus, Charlestown, MA, USA
3 shared publications - Alexandra Veloso
Molecular Pathology Unit, Massachusetts General Research Institute, Harvard Medical School, Charlestown, MA, USA
2 shared publications - Chuan Yan
Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore
2 shared publications - Eric J. Alpert
Department of Pathology and Center for Cancer Research, Massachusetts General Hospital, Charlestown, MA
2 shared publications Lauren Whelton
Molecular Pathology Unit, Massachusetts General Hospital, Charlestown, USA
2 shared publications- Xueji Zhang
Shenzhen University
2 shared publications
Latest Publications
- Open Access
- 10 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
The PIK3CA/AKT pathway drives therapy resistance in rhabdomyosarcoma
Olaparib and temozolomide (OT) combination therapy is in clinical trial evaluation for rhabdomyosarcoma (RMS). Unfortunately, OT resistance has been reported in other cancers. Using preclinical mouse xenograft experiments, we show that OT effectively suppresses RMS growth, yet over half of RMS tumors develop resistance associated with transcriptomic changes that occur in the absence of recurrent genomic mutation. Importantly, most resistant RMS models upregulate the PIK3CA/AKT pathway, activating NRF2 phosphorylation and subsequent transcriptional expression of multidrug resistance ABC transporters. PIK3CA inhibitor alpelisib re-sensitizes resistant cells to OT by suppressing expression of ABC transporters. The combination of OT + alpelisib also kills RMS cells which are resistant to standard-of-care combination chemotherapy and was effective in preclinical xenograft mouse models at curbing tumor growth. Our work defines a common resistance pathway in RMS and has credentialled PIK3CA/AKT inhibition as a preclinical strategy to kill therapy resistant RMS.
- 10 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessThe PIK3CA/AKT pathway drives therapy resistance in rhabdomyosarcoma
Olaparib and temozolomide (OT) combination therapy is in clinical trial evaluation for rhabdomyosarcoma (RMS). Unfortunately, OT resistance has been reported in other cancers. Using preclinical mouse xenograft experiments, we show that OT effectively suppresses RMS growth, yet over half of RMS tumors develop resistance associated with transcriptomic changes that occur in the absence of recurrent genomic mutation. Importantly, most resistant RMS models upregulate the PIK3CA/AKT pathway, activating NRF2 phosphorylation and subsequent transcriptional expression of multidrug resistance ABC transporters. PIK3CA inhibitor alpelisib re-sensitizes resistant cells to OT by suppressing expression of ABC transporters. The combination of OT + alpelisib also kills RMS cells which are resistant to standard-of-care combination chemotherapy and was effective in preclinical xenograft mouse models at curbing tumor growth. Our work defines a common resistance pathway in RMS and has credentialled PIK3CA/AKT inhibition as a preclinical strategy to kill therapy resistant RMS.
- Open Access
- 1 March 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (9) , eadj4698
The FLRT3-UNC5B checkpoint pathway inhibits T cell–based cancer immunotherapies
Cancers exploit coinhibitory receptors on T cells to escape tumor immunity, and targeting such mechanisms has shown remarkable clinical benefit, but in a limited subset of patients. We hypothesized that cancer cells mimic noncanonical mechanisms of early development such as axon guidance pathways to evade T cell immunity. Using gain-of-function genetic screens, we profiled axon guidance proteins on human T cells and their cognate ligands and identified fibronectin leucine-rich transmembrane protein 3 (FLRT3) as a ligand that inhibits T cell activity. We demonstrated that FLRT3 inhibits T cells through UNC5B, an axon guidance receptor that is up-regulated on activated human T cells. FLRT3 expressed in human cancers favored tumor growth and inhibited CAR-T and BiTE + T cell killing and infiltration in humanized cancer models. An FLRT3 monoclonal antibody that blocked FLRT3-UNC5B interactions reversed these effects in an immune-dependent manner. This study supports the concept that axon guidance proteins mimic T cell checkpoints and can be targeted for cancer immunotherapy.
- 1 March 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (9) , eadj4698
Open AccessThe FLRT3-UNC5B checkpoint pathway inhibits T cell–based cancer immunotherapies
Cancers exploit coinhibitory receptors on T cells to escape tumor immunity, and targeting such mechanisms has shown remarkable clinical benefit, but in a limited subset of patients. We hypothesized that cancer cells mimic noncanonical mechanisms of early development such as axon guidance pathways to evade T cell immunity. Using gain-of-function genetic screens, we profiled axon guidance proteins on human T cells and their cognate ligands and identified fibronectin leucine-rich transmembrane protein 3 (FLRT3) as a ligand that inhibits T cell activity. We demonstrated that FLRT3 inhibits T cells through UNC5B, an axon guidance receptor that is up-regulated on activated human T cells. FLRT3 expressed in human cancers favored tumor growth and inhibited CAR-T and BiTE + T cell killing and infiltration in humanized cancer models. An FLRT3 monoclonal antibody that blocked FLRT3-UNC5B interactions reversed these effects in an immune-dependent manner. This study supports the concept that axon guidance proteins mimic T cell checkpoints and can be targeted for cancer immunotherapy.
- Open Access
- 27 October 2022
- Published by American Society of Hematology in Blood
- Vol. 140 (17) , 1891-1906
Therapeutic targeting of LCK tyrosine kinase and mTOR signaling in T-cell acute lymphoblastic leukemia
Relapse and refractory T-cell acute lymphoblastic leukemia (T-ALL) has a poor prognosis, and new combination therapies are sorely needed. Here, we used an ex vivo high-throughput screening platform to identify drug combinations that kill zebrafish T-ALL and then validated top drug combinations for preclinical efficacy in human disease. This work uncovered potent drug synergies between AKT/mTORC1 (mammalian target of rapamycin complex 1) inhibitors and the general tyrosine kinase inhibitor dasatinib. Importantly, these same drug combinations effectively killed a subset of relapse and dexamethasone-resistant zebrafish T-ALL. Clinical trials are currently underway using the combination of mTORC1 inhibitor temsirolimus and dasatinib in other pediatric cancer indications, leading us to prioritize this therapy for preclinical testing. This combination effectively curbed T-ALL growth in human cell lines and primary human T-ALL and was well tolerated and effective in suppressing leukemia growth in patient-derived xenografts (PDX) grown in mice. Mechanistically, dasatinib inhibited phosphorylation and activation of the lymphocyte-specific protein tyrosine kinase (LCK) to blunt the T-cell receptor (TCR) signaling pathway, and when complexed with mTORC1 inhibition, induced potent T-ALL cell killing through reducing MCL-1 protein expression. In total, our work uncovered unexpected roles for the LCK kinase and its regulation of downstream TCR signaling in suppressing apoptosis and driving continued leukemia growth. Analysis of a wide array of primary human T-ALLs and PDXs grown in mice suggest that combination of temsirolimus and dasatinib treatment will be efficacious for a large fraction of human T-ALLs.
- 27 October 2022
- Published by American Society of Hematology in Blood
- Vol. 140 (17) , 1891-1906
Open AccessTherapeutic targeting of LCK tyrosine kinase and mTOR signaling in T-cell acute lymphoblastic leukemia
Relapse and refractory T-cell acute lymphoblastic leukemia (T-ALL) has a poor prognosis, and new combination therapies are sorely needed. Here, we used an ex vivo high-throughput screening platform to identify drug combinations that kill zebrafish T-ALL and then validated top drug combinations for preclinical efficacy in human disease. This work uncovered potent drug synergies between AKT/mTORC1 (mammalian target of rapamycin complex 1) inhibitors and the general tyrosine kinase inhibitor dasatinib. Importantly, these same drug combinations effectively killed a subset of relapse and dexamethasone-resistant zebrafish T-ALL. Clinical trials are currently underway using the combination of mTORC1 inhibitor temsirolimus and dasatinib in other pediatric cancer indications, leading us to prioritize this therapy for preclinical testing. This combination effectively curbed T-ALL growth in human cell lines and primary human T-ALL and was well tolerated and effective in suppressing leukemia growth in patient-derived xenografts (PDX) grown in mice. Mechanistically, dasatinib inhibited phosphorylation and activation of the lymphocyte-specific protein tyrosine kinase (LCK) to blunt the T-cell receptor (TCR) signaling pathway, and when complexed with mTORC1 inhibition, induced potent T-ALL cell killing through reducing MCL-1 protein expression. In total, our work uncovered unexpected roles for the LCK kinase and its regulation of downstream TCR signaling in suppressing apoptosis and driving continued leukemia growth. Analysis of a wide array of primary human T-ALLs and PDXs grown in mice suggest that combination of temsirolimus and dasatinib treatment will be efficacious for a large fraction of human T-ALLs.
- 21 April 2022
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 94 (17) , 6599-6606
Endogenous MicroRNA Accurate Diagnostics to Guide Photothermal Therapy
Developing an intelligent theranostic nanoplatform with satisfied diagnostic accuracy and therapeutic efficiency holds great promise for personalized nanomedicine. Herein, we constructed a smart nanodevice for the accurate diagnosis of endogenous cancer microRNA (miRNA) biomarkers and efficient photothermal therapy (PTT). The nanodevice was composed of polydopamine (PDA)-functionalized CuS nanosheets (CuS@PDA NSs) and three elaborate DNA hairpin probes (TDHPs). The CuS@PDA NSs acted as efficient delivery vehicles and photothermal agents. They provided a large surface area available for an efficient and facile loading of TDHPs and a high-fluorescence (FL) quenching performance to achieve an ultralow background signal. The intracellular miRNA triggered TDHPs to assemble into three-arm branched junction structures for a strong fluorescence recovery as output signals to discriminate cancer cells from normal cells with an excellent sensitivity. The CuS@PAD NSs showed a good photothermal conversion efficiency in the near-infrared II (NIR II) region to mediate a good photothermal performance to kill cancer cells. A remarkable antitumor therapeutic effect was achieved in vivo. This work integrated highly sensitive detection to endogenous cancer biomarkers and valid therapeutic potency to tumor-bearing mice, indicating its promising biomedical applications.
- 21 April 2022
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 94 (17) , 6599-6606
Endogenous MicroRNA Accurate Diagnostics to Guide Photothermal Therapy
Developing an intelligent theranostic nanoplatform with satisfied diagnostic accuracy and therapeutic efficiency holds great promise for personalized nanomedicine. Herein, we constructed a smart nanodevice for the accurate diagnosis of endogenous cancer microRNA (miRNA) biomarkers and efficient photothermal therapy (PTT). The nanodevice was composed of polydopamine (PDA)-functionalized CuS nanosheets (CuS@PDA NSs) and three elaborate DNA hairpin probes (TDHPs). The CuS@PDA NSs acted as efficient delivery vehicles and photothermal agents. They provided a large surface area available for an efficient and facile loading of TDHPs and a high-fluorescence (FL) quenching performance to achieve an ultralow background signal. The intracellular miRNA triggered TDHPs to assemble into three-arm branched junction structures for a strong fluorescence recovery as output signals to discriminate cancer cells from normal cells with an excellent sensitivity. The CuS@PAD NSs showed a good photothermal conversion efficiency in the near-infrared II (NIR II) region to mediate a good photothermal performance to kill cancer cells. A remarkable antitumor therapeutic effect was achieved in vivo. This work integrated highly sensitive detection to endogenous cancer biomarkers and valid therapeutic potency to tumor-bearing mice, indicating its promising biomedical applications.
- 1 March 2022
- Published by Elsevier in Materials Today Chemistry
- Vol. 23, 100609
Biohybrid bacterial microswimmers with metal-organic framework exoskeletons enable cytoprotection and active drug delivery in a harsh environment
- 1 March 2022
- Published by Elsevier in Materials Today Chemistry
- Vol. 23, 100609
Biohybrid bacterial microswimmers with metal-organic framework exoskeletons enable cytoprotection and active drug delivery in a harsh environment
- Open Access
- 20 August 2021
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 218 (10)
Single-cell imaging of T cell immunotherapy responses in vivo
T cell immunotherapies have revolutionized treatment for a subset of cancers. Yet, a major hurdle has been the lack of facile and predicative preclinical animal models that permit dynamic visualization of T cell immune responses at single-cell resolution in vivo. Here, optically clear immunocompromised zebrafish were engrafted with fluorescent-labeled human cancers along with chimeric antigen receptor T (CAR T) cells, bispecific T cell engagers (BiTEs), and antibody peptide epitope conjugates (APECs), allowing real-time single-cell visualization of T cell–based immunotherapies in vivo. This work uncovered important differences in the kinetics of T cell infiltration, tumor cell engagement, and killing between these immunotherapies and established early endpoint analysis to predict therapy responses. We also established EGFR-targeted immunotherapies as a powerful approach to kill rhabdomyosarcoma muscle cancers, providing strong preclinical rationale for assessing a wider array of T cell immunotherapies in this disease.
- 20 August 2021
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 218 (10)
Open AccessSingle-cell imaging of T cell immunotherapy responses in vivo
T cell immunotherapies have revolutionized treatment for a subset of cancers. Yet, a major hurdle has been the lack of facile and predicative preclinical animal models that permit dynamic visualization of T cell immune responses at single-cell resolution in vivo. Here, optically clear immunocompromised zebrafish were engrafted with fluorescent-labeled human cancers along with chimeric antigen receptor T (CAR T) cells, bispecific T cell engagers (BiTEs), and antibody peptide epitope conjugates (APECs), allowing real-time single-cell visualization of T cell–based immunotherapies in vivo. This work uncovered important differences in the kinetics of T cell infiltration, tumor cell engagement, and killing between these immunotherapies and established early endpoint analysis to predict therapy responses. We also established EGFR-targeted immunotherapies as a powerful approach to kill rhabdomyosarcoma muscle cancers, providing strong preclinical rationale for assessing a wider array of T cell immunotherapies in this disease.